Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immunic, Inc.

1.15
+0.03002.68%
Post-market: 1.13-0.0200-1.74%17:13 EDT
Volume:534.22K
Turnover:608.67K
Market Cap:103.59M
PE:-1.02
High:1.17
Open:1.12
Low:1.10
Close:1.12
Loading ...

Immunic Is Maintained at Buy by EF Hutton

Dow Jones
·
22 Oct 2024

BUZZ-Immunic jumps on interim late-stage data for multiple sclerosis drug

Reuters
·
22 Oct 2024

Immunic Shares up 23.2% Premarket After Co Reports Interim Late-Stage Study Data for Experimental Multiple Sclerosis Drug

THOMSON REUTERS
·
22 Oct 2024

Immunic Inc: Ensure Program Remains on Track to Be Completed in 2026

THOMSON REUTERS
·
22 Oct 2024

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

THOMSON REUTERS
·
22 Oct 2024

Immunic: Idmc Recommended Continuing Trial Without Changes, Including No Need for Potential Upsizing

THOMSON REUTERS
·
22 Oct 2024

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

PR Newswire
·
22 Oct 2024

Immunic Stock Set to Rise with Consistent Buy Ratings from Analysts

TIPRANKS
·
21 Oct 2024

Immunic price target raised to $13 from $10 at Brookline

TIPRANKS
·
16 Oct 2024

Top Premarket Gainers

MT Newswires Live
·
11 Oct 2024

Immunic Inc (IMUX) Q2 2024 Earnings Call Highlights: Promising Clinical Data and Financial ...

GuruFocus.com
·
10 Oct 2024

B. Riley Reacts to Immunic’s Update on Clinical Benefits of Vidofludimus Calcium

TIPRANKS
·
01 Oct 2024

Immunic’s MS Drug Candidate Shows Promising Future: A Comprehensive Buy Rating Justification

TIPRANKS
·
24 Sep 2024

Immunic, Inc.'s (NASDAQ:IMUX) high hedge funds ownership speaks for itself as stock continues to impress, up 18% over last week

Simply Wall St.
·
19 Sep 2024

Immunic Says Initial Phase 2 Data Back Vidofludimus Calcium's Potential in Multiple Sclerosis

MT Newswires Live
·
18 Sep 2024

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

PR Newswire
·
18 Sep 2024